About Apolipoprotein(a)
Apolipoprotein(a) (LPA) is a protein
from Homo sapiens identified by UniProt accession
P08519, 2040 residues long.
MolForge cross-references it against 0 known binders and
501 disease associations.
Target properties
| Protein name | Apolipoprotein(a) |
|---|
| UniProt accession | P08519 |
|---|
| Gene | LPA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2040 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (501)
Diseases linked to this target (Open Targets).
- lipoprotein A measurement · score 0.72
- cardiovascular disease · score 0.61
- coronary artery disease · score 0.57
- low density lipoprotein cholesterol measurement · score 0.54
- myocardial infarction · score 0.54
- angina pectoris · score 0.53
- total cholesterol measurement · score 0.53
- high density lipoprotein cholesterol measurement · score 0.53
- parental longevity · score 0.52
- drug use measurement · score 0.52
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P08519-F1 | alphafold | PREDICTED | 60.05 | — |
Amino-acid sequence (2040 residues)
MEHKEVVLLL LLFLKSAAPE QSHVVQDCYH GDGQSYRGTY STTVTGRTCQ AWSSMTPHQH NRTTENYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDA VAAPYCYTRD PGVRWEYCNL TQCSDAEGTA VAPPTVTPVP SLEAPSEQAP TEQRPGVQEC YHGNGQSYRG TYSTTVTGRT CQAWSSMTPH SHSRTPEYYP NAGLIMNYCR NPDAVAAPYC YTRDPGVRWE YCNLTQCSDA EGTAVAPPTV TPVPSLEAPS EQAPTEQRPG VQECYHGNGQ SYRGTYSTTV TGRTCQAWSS MTPHSHSRTP EYYPNAGLIM NYCRNPDAVA APYCYTRDPG VRWEYCNLTQ CSDAEGTAVA PPTVTPVPSL EAPSEQAPTE QRPGVQECYH GNGQSYRGTY STTVTGRTCQ AWSSMTPHSH SRTPEYYPNA GLIMNYCRNP DAVAAPYCYT RDPGVRWEYC NLTQCSDAEG TAVAPPTVTP VPSLEAPSEQ APTEQRPGVQ ECYHGNGQSY RGTYSTTVTG RTCQAWSSMT PHSHSRTPEY YPNAGLIMNY CRNPDAVAAP YCYTRDPGVR WEYCNLTQCS DAEGTAVAPP TVTPVPSLEA PSEQAPTEQR PGVQECYHGN GQSYRGTYST TVTGRTCQAW SSMTPHSHSR TPEYYPNAGL IMNYCRNPDP VAAPYCYTRD PSVRWEYCNL TQCSDAEGTA VAPPTITPIP SLEAPSEQAP TEQRPGVQEC YHGNGQSYQG TYFITVTGRT CQAWSSMTPH SHSRTPAYYP NAGLIKNYCR NPDPVAAPWC YTTDPSVRWE YCNLTRCSDA EWTAFVPPNV ILAPSLEAFF EQALTEETPG VQDCYYHYGQ SYRGTYSTTV TGRTCQAWSS MTPHQHSRTP ENYPNAGLTR NYCRNPDAEI RPWCYTMDPS VRWEYCNLTQ CLVTESSVLA TLTVVPDPST EASSEEAPTE QSPGVQDCYH GDGQSYRGSF STTVTGRTCQ SWSSMTPHWH QRTTEYYPNG GLTRNYCRNP DAEISPWCYT MDPNVRWEYC NLTQCPVTES SVLATSTAVS EQAPTEQSPT VQDCYHGDGQ SYRGSFSTTV TGRTCQSWSS MTPHWHQRTT EYYPNGGLTR NYCRNPDAEI RPWCYTMDPS VRWEYCNLTQ CPVMESTLLT TPTVVPVPST ELPSEEAPTE NSTGVQDCYR GDGQSYRGTL STTITGRTCQ SWSSMTPHWH RRIPLYYPNA GLTRNYCRNP DAEIRPWCYT MDPSVRWEYC NLTRCPVTES SVLTTPTVAP VPSTEAPSEQ APPEKSPVVQ DCYHGDGRSY RGISSTTVTG RTCQSWSSMI PHWHQRTPEN YPNAGLTENY CRNPDSGKQP WCYTTDPCVR WEYCNLTQCS ETESGVLETP TVVPVPSMEA HSEAAPTEQT PVVRQCYHGN GQSYRGTFST TVTGRTCQSW SSMTPHRHQR TPENYPNDGL TMNYCRNPDA DTGPWCFTMD PSIRWEYCNL TRCSDTEGTV VAPPTVIQVP SLGPPSEQDC MFGNGKGYRG KKATTVTGTP CQEWAAQEPH RHSTFIPGTN KWAGLEKNYC RNPDGDINGP WCYTMNPRKL FDYCDIPLCA SSSFDCGKPQ VEPKKCPGSI VGGCVAHPHS WPWQVSLRTR FGKHFCGGTL ISPEWVLTAA HCLKKSSRPS SYKVILGAHQ EVNLESHVQE IEVSRLFLEP TQADIALLKL SRPAVITDKV MPACLPSPDY MVTARTECYI TGWGETQGTF GTGLLKEAQL LVIENEVCNH YKYICAEHLA RGTDSCQGDS GGPLVCFEKD KYILQGVTSW GLGCARPNKP GVYARVSRFV TWIEGMMRNN
Explore Apolipoprotein(a) with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets